The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 348:2618-2625 June 26, 2003 Number 26
NextNext

Outpatient Oral Prednisone after Emergency Treatment of Chronic Obstructive Pulmonary Disease
Shawn D. Aaron, M.D., Katherine L. Vandemheen, B.Sc.N., Paul Hebert, M.D., Robert Dales, M.D., Ian G. Stiell, M.D., Jan Ahuja, M.D., Garth Dickinson, M.D., Robert Brison, M.D., M.P.H., Brian H. Rowe, M.D., Jonathan Dreyer, M.D., Elizabeth Yetisir, M.Sc., Daniel Cass, M.D., and George Wells, Ph.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Editorial
 by Irwin, R. S.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background In this randomized, double-blind, placebo-controlled trial, we studied the effectiveness of prednisone in reducing the risk of relapse after outpatient exacerbations of chronic obstructive pulmonary disease (COPD).

Methods We enrolled 147 patients who were being discharged from the emergency department after an exacerbation of COPD and randomly assigned them to 10 days of treatment with 40 mg of oral prednisone once daily or identical-appearing placebo. All patients received oral antibiotics for 10 days, plus inhaled bronchodilators. The primary end point was relapse, defined as an unscheduled visit to a physician's office or a return to the emergency department because of worsening dyspnea, within 30 days after randomization.

Results The overall rate of relapse at 30 days was lower in the prednisone group than in the placebo group (27 percent vs. 43 percent, P=0.05), and the time to relapse was prolonged in those taking prednisone (P=0.04). After 10 days of therapy, patients in the prednisone group had greater improvements in forced expiratory volume in one second than did patients in the placebo group (mean [±SD] increase from base line, 34±42 percent vs. 15±31 percent; P=0.007). Patients in the prednisone group also had significant improvements in dyspnea, as measured by the transitional dyspnea index (P=0.04) and by the dyspnea domain of the Chronic Respiratory Disease Index Questionnaire (P=0.02), but not in health-related quality of life (P=0.14).

Conclusions Outpatient treatment with oral prednisone offers a small advantage over placebo in treating patients who are discharged from the emergency department with an exacerbation of COPD.


Source Information

From the Departments of Medicine (S.D.A., P.H., R.D.) and Emergency Medicine (I.G.S, J.A., G.D.), and the Ottawa Health Research Institute (K.L.V., E.Y., G.W.), University of Ottawa, Ottawa, Ont.; the Department of Emergency Medicine, Queen's University, Kingston, Ont. (R.B.); the Division of Emergency Medicine, University of Alberta, Edmonton, Alta. (B.H.R.); the Department of Emergency Medicine, London Health Sciences Centre, London, Ont. (J.D.); and St. Michael's Hospital, Toronto (D.C.) — all in Canada.

Address reprint requests to Dr. Aaron at the Division of Respiratory Medicine, Ottawa Hospital, General Campus, Rm. 1812F, 501 Smyth Rd., Ottawa, ON K1H 8L6, Canada, or at saaron{at}ottawahospital.on.ca.

Full Text of this Article


Related Letters:

Prednisone for Chronic Obstructive Pulmonary Disease
Busti A. J., Vervan M. D., Brouse S. D., Hurst J. R., Donaldson G. C., Wedzicha J. A., Rolla G., Bucca C., Salloum A., Elbaage T. Y., Soubani A. O., Aaron S., Dales R., Wells G.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:1288-1290, Sep 25, 2003. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.